Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
Catherine Z. Chen(National Institutes of Health), Wei Zheng(Liaoning Cancer Hospital & Institute), Kelli M. Wilson(National Institutes of Health), Ruili Huang(National Institutes of Health), Matthew D. Hall(National Institutes of Health), Brianna M. Brooks(National Center for Advancing Translational Sciences), Robert Bostwick(Southern Research Institute), Zina Itkin(National Institutes of Health), Carleen Klump-Thomas(National Center for Advancing Translational Sciences), Tongan Zhao(National Center for Advancing Translational Sciences), Lynn Rasmussen, Sam Michael(National Institutes of Health), Anton Simeonov(National Institutes of Health), Min Shen(Kaili University), Xin Hu(Discovery Institute), Hui Guo(First Affiliated Hospital of Xi'an Jiaotong University), Donald C. Lo(Center for Translational Molecular Medicine), Paul Shinn(National Institutes of Health), Richard T. Eastman(National Institutes of Health)
Cited by 30
Related Papers
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
|Nature Medicine|2016|570
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|391
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Erratum: Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|327